Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03907241
Other study ID # SCGAM-03 -
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 1, 2016
Est. completion date September 5, 2019

Study information

Verified date October 2020
Source Octapharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial


Other known NCT identifiers
  • NCT02627300

Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date September 5, 2019
Est. primary completion date September 5, 2019
Accepts healthy volunteers No
Gender All
Age group 2 Years to 75 Years
Eligibility Inclusion Criteria for SCGAM-03: 1. Completion of the main study SCGAM-01, with good tolerance of Octanorm (as determined by the investigator). 2. For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with local requirements. 3. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening visit. 4. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study. Inclusion Criteria for SCGAM-03 in Canada: Either: SCGAM-01 patients (United States, Canada): 1. Completion of the main study SCGAM-01, with good tolerance of octanorm (as determined by the investigator). Or: De novo patients (Canada only): 1. C-a Age of =18 years and =75 years. 1C-b Confirmed diagnosis of PI as defined by ESID and PAGID and requiring immunoglobulin replacement therapy due to hypogammaglobulinaemia or agammaglobulinaemia. The exact type of PI should be recorded. 1. C-c Availability of the IgG trough levels of 2 previous SCIG infusions before enrolment, and maintenance of =5.0 g/L in the trough levels of these 2 previous infusions. And: 2. For adult patients: freely given written informed consent. For patients below the legal age of majority: freely given written informed consent from parents/legal guardians and written informed assent from the child/adolescent in accordance with local requirements. 3. For female patients of child-bearing potential, a negative result in a urine pregnancy test conducted at the Screening Visit. 4. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study. Exclusion Criteria for SCGAM-03: 1. Subject being without any IgG treatment for period greater than approximately 5 weeks between the last infusion of Octanorm in the SCGAM-01 study and the first infusion of Octanorm in the SCGAM-03 study. 2. Exposure to blood or any blood product or derivative, other than IgG used for regular PID treatment, within the 3 months before the first infusion in this study. 3. Planned pregnancy during the course of the study. Exclusion Criteria for SCGAM-03 in Canada: - Either: SCGAM-01 patients (United States, Canada): 1 Subject being without any IgG treatment for period greater than 5 weeks between the last infusion of octanorm in the SCGAM-01 study and the first infusion of octanorm in the SCGAM-03 study. Or: De novo patients (Canada only): 1C-a Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and during the screening period. 1C-b Known history of adverse reactions to IgA in other products. 1C-c Patients with body mass index >40 kg/m2. 1C-d Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product (such as Polysorbate 80). 1C-e Requirement of any routine premedication for IgG administration. 1C-f History of malignancies of lymphoid cells and immunodeficiency with lymphoma. 1C-g Severe liver function impairment (ALAT 3 times above upper limit of normal). 1C-h Known protein-losing enteropathies or proteinuria. 1C-i Presence of renal function impairment (creatinine >120 µM/L or creatinine >1.35 mg/dL), or predisposition for acute renal failure (e.g., any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs). 1C-j Treatment with oral or parenteral steroids for =30 days or when given intermittently or as bolus at daily doses =0.15 mg/kg. 1C-k Treatment with immunosuppressive or immunomodulatory drugs. 1C-l Live viral vaccination (such as measles, rubella, mumps and varicella) within the last 2 months prior to first infusion of octanorm. And: 2. Exposure to blood or any blood product or plasma derivatives, other than SCIG used for regular PID treatment, within the 3 months before the first infusion of octanorm in this study. 3. Pregnant or nursing women or planned pregnancy during the course of the study. 4. Treatment with any investigational medicinal product (other than that of SCGAM-01) within 3 months prior to first infusion of octanorm. 5. Presence of any condition, that is likely to interfere with the evaluation of study medication or satisfactory conduct of the trial. 6. Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the past 12 months prior to first infusion of octanorm. 7. Known or suspected HIV, HCV, or HBV infection.

Study Design


Intervention

Drug:
Octanorm 16.5%
Human normal immunoglobulin

Locations

Country Name City State
Canada Octapharma Research Site Edmonton Alberta
United States Octapharma Research Site Centennial Colorado
United States Octapharma Research Site Frisco Texas
United States Octapharma Research Site Irvine California
United States Octapharma Research Site Papillion Nebraska
United States Octapharma Research Site San Diego California
United States Octapharma Research Site Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
Octapharma

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of All Treatment-emergent Adverse Events (TEAEs) Number of TEAEs From study start to end, up to 3.5 years
Primary Occurrence of Temporally Associated TEAEs From study start to end, up to 3.5 years
Primary Number of Temporally Associated TEAEs by Infusion Rate Number of temporally associated TEAEs by infusion rate. Only includes systemic TEAEs without infections and without infusion site reactions From study start to end, up to 3.5 years
Primary Local Injection-site Reactions From study start to end, up to 3.5 years
Primary Blood Pressure Systolic and diastolic. From study start to end, up to 3.5 years
Primary Body Temperature From study start to end, up to 3.5 years
Primary Respiratory Rate From study start to end, up to 3.5 years
Primary Sodium Changes in sodium levels from baseline to end of study From study start to end, up to 3.5 years
Primary Potassium Changes in potassium levels from baseline to end of study From study start to end, up to 3.5 years
Primary Blood Glucose Changes in blood glucose from baseline to end of study From study start to end, up to 3.5 years
Primary ALAT Changes in ALAT (alanine transaminase) from baseline to end of study From study start to end, up to 3.5 years
Primary ASAT Changes in ASAT (aspartate aminotransferase) from baseline to end of study From study start to end, up to 3.5 years
Primary LDH Changes in LDH (lactate dehydrogenase) from baseline to end of study From study start to end, up to 3.5 years
Primary Total Bilirubin Changes in total bilirubin from baseline to end of study From study start to end, up to 3.5 years
Primary Blood Urea Nitrogen Changes in blood urea nitrogen from baseline to end of study From study start to end, up to 3.5 years
Primary Creatinine Changes in creatinine from baseline to end of study From study start to end, up to 3.5 years
Primary Urine pH Changes in urine pH from baseline to end of study From study start to end, up to 3.5 years
Primary Number of Participants With a Change in Urine Glucose Number of Participants with a Change in Urine Glucose From study start to end, up to 3.5 years
Primary Number of Participants With a Change in Urine Ketones Number of Participants With a Change in Urine Ketones at baseline and end of study From study start to end, up to 3.5 years
Primary Number of Participants With a Change in Urine Leukocytes Number of participants with a change in urine leukocytes at baseline and end of study From study start to end, up to 3.5 years
Primary Number of Participants With a Change in Urine Hemoglobin Number of participants with a change in urine hemoglobin at baseline and end of study From study start to end, up to 3.5 years
Primary Complete Red Blood Cell Count Changes in complete red blood cell count from baseline to end of study From study start to end, up to 3.5 years
Primary Haematocrit Changes in haematocrit from baseline to end of study From study start to end, up to 3.5 years
Primary Haemoglobin Changes in haemoglobin from baseline to end of study From study start to end, up to 3.5 years
Primary Complete White Blood Cell Count Changes in complete white blood cell count from baseline to end of study From study start to end, up to 3.5 years
Secondary Measurement of Trough Total IgG Levels Measurement of trough total IgG levels from baseline to end of study From study start to end, up to 3.5 years
Secondary Number of Participants With Serious Bacterial Infections (SBIs). Number of participants with serious bacterial infections From study start to end, up to 3.5 years
Secondary SF-36 Health Survey. Quality of Life for patients >= age 14 assessed using the Short Form 36 Health survey. Likert like scale.
The responses given by patients were combined to create 8 SF-36 scores: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, mental health
36 questions that fall into 4 Sub scale scoring ranges: Score 1-5: Where 1 is more favorable than 5 Score 1-3: Where 3 is more favorable than 1 Score 1-5: Where 5 is more favorable than 1 Score 1-6: Where 1 is more favorable than 6 The raw subscale scores are converted into a scale score between 0 to 100 using the Quality Metric Health Outcomes™ Scoring Software 2.0 Scale Title of final scales is: Physical and Mental Health Component Summary Scores Range: Lowest = 0 and highest = 100 where a high score equates to a more favorable health state
From study start to end, up to 3.5 years
Secondary CHQ-PF50 (Child Health Questionnaire-Parent Form) Quality of Life for patients ages <14 years assessed using the CHQ-PF50. Measured values represent change in score from baseline to end of study.
Two summary scores were derived: physical and psychosocial. In accord with the scoring manual, computed scores were transformed giving each scale a possible range from 0 to 100, with the exception of change in health, with a possible range from 1 to 5. For all CHQ-PF50 scales, higher scores indicated more positive functioning or better health status.
From study start to end, up to 3.5 years
See also
  Status Clinical Trial Phase
Completed NCT04561115 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT06355323 - Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France N/A
Completed NCT04566692 - A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency Phase 4
Completed NCT01465958 - Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency Phase 4
Completed NCT01581593 - Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) Phase 3
Completed NCT02881437 - IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia Phase 4
Recruiting NCT06092528 - Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency N/A
Active, not recruiting NCT03576742 - Severe Immune Cytopenia Registry Www.Sic-reg.Org
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Completed NCT02806986 - Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3
Completed NCT03339778 - The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations N/A
Enrolling by invitation NCT00895271 - Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Recruiting NCT03206099 - NIAID Centralized Sequencing Protocol
Completed NCT02503293 - A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Phase 4
Recruiting NCT03610802 - Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies
Completed NCT03815357 - What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
Completed NCT02269163 - Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% Phase 3
Terminated NCT03733249 - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Phase 1/Phase 2
Not yet recruiting NCT02123615 - ASIS for GAMMAGARD in Primary Immunodeficiency Phase 1/Phase 2
Completed NCT02604810 - Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency Phase 3